SCHEMBL5554014

SCHEMBL5554014

Cc1c(CCC(=O)NCCC(=O)O)c2c(F)c(O)ccc2n1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.55
AKR1C2 P52895 4/20 0.55
PTGS1 P23219 8/20 0.48
PTGS2 P35354 14/20 0.46
ABCB1 P08183 2/20 0.43
HRH4 Q9H3N8 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
PTGES O14684 1/20 0.41
ABCC3 O15438 1/20 0.41
ABCC4 O15439 1/20 0.41
ABCB11 O95342 1/20 0.41
MT-CO2 P00403 1/20 0.41
LMNA P02545 1/20 0.41
ALB P02768 1/20 0.41
CYP1A2 P05177 1/20 0.41
ALOX5 P09917 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CXCL8 P10145 1/20 0.41
AR P10275 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5800042 0.92 PTGS2 (0.53) AKR1C3AKR1C2PTGS1PTGS2ABCB1
SCHEMBL6425462 0.90 AKR1C3 (0.46) AKR1C3AKR1C2PTGS1PTGS2HRH4
SCHEMBL5811169 0.90 AKR1C3 (0.45) AKR1C3AKR1C2PTGS1PTGS2HRH4
SCHEMBL5561446 0.89 AKR1C3 (0.45) AKR1C3AKR1C2PTGS1PTGS2HRH4
SCHEMBL5558893 0.89 AKR1C3 (0.45) AKR1C3AKR1C2PTGS1PTGS2MEN1
SCHEMBL5554399 0.88 AKR1C3 (0.54) AKR1C3AKR1C2PTGS1PTGS2ABCB1
SCHEMBL5811222 0.87 AKR1C3 (0.48) AKR1C3AKR1C2PTGS1PTGS2ABCB1
SCHEMBL5554113 0.87 AKR1C3 (0.41) AKR1C3AKR1C2PTGS1PTGS2PPARG
SCHEMBL5808235 0.85 AKR1C3 (0.44) AKR1C3AKR1C2PTGS1PTGS2KDM4E
SCHEMBL6423910 0.85 AKR1C3 (0.50) AKR1C3AKR1C2PTGS1PTGS2ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643961-A4 COX-2 AND FAAH INHIBITORS MICROBIA INC (US) 2007-09-12 EP disclosed
EP-1643961-A2 COX-2 AND FAAH INHIBITORS Microbia, Inc. (US) 2006-04-12 EP disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed
WO-2005002525-A2 COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 AKR1C3 585/4885AKR1C2 342/4885PTGS1 6/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885PTGS1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.